An observational study in Glioma, sponsored by iOMEDICO AG. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.
Sponsored by iOMEDICO AG · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Glioma with a site in Germany — 20 open to participants now, 29 under way, 3 of them phase 3. Glioma · Germany.
Among the 70 studies in Glioma with a site in Germany, this one is the 6th largest by planned enrollment of the 11 observational ones that give a count, is one of 7 that started in 2025, is one of 11 observational ones, reaches primary completion later than 26 of the 28 other live ones, and was the 66th registered.
1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.
Browse Glioma studies →20 of the 70 studies in Glioma with a site in Germany are open now. Recruiting first, the newest first:
Nationwide Children's Hospital · Sites in Germany, United States, Australia and 3 more countries
Ages 1–21 · Healthy volunteers
LMU Klinikum · Sites in Germany, Austria
Ages 18+
Nationwide Children's Hospital · Sites in Germany, United States, Australia and 2 more countries
Ages 12 mo–39 yrs
Rigel Pharmaceuticals · Sites in Germany, United States, Australia and 4 more countries
Ages 12–39
Nationwide Children's Hospital · Sites in Germany, United States, Australia and 3 more countries
Ages 12 mo–39 yrs
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 25 · Phase 3 11 · Phase 4 2
First in 1996; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 90 across 274 observational studies indexed under Glioma.
Median enrollment 74 across the 58 interventional studies, 150 across the 11 observational. Of the 33 that completed or were terminated, 10 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 70 have an industry lead sponsor. The 10 most frequent:
iOMEDICO AG is the lead sponsor of 53 studies on the registry; 14 are open to participants now.
iOMEDICO AG has 1 study filed under Glioma — fewer than ten, so there is no comparison to draw.
8 of the studies in Glioma with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04808245German Cancer Research CenterA MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas | 2026-11 |
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT04655404Nationwide Children's HospitalA Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | 2026-12-01 |
| NCT02686229University of UlmRegistry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 70 studies in Glioma with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this prospective, observational study VIOLETA is to collect real-world data on vorasidenib treatment in a broad patient population. Though vorasidenib can be administered from 12 years old, VIOLETA focuses on adult patients with IDH1- or IDH2-mutant WHO grade 2 glioma who receive vorasidenib following surgery according to the current SmPC. Thus, VIOLETA will evaluate for the first-time treatment with vorasidenib in German clinical routine. To gain knowledge about how vorasidenib treatment affects patients' well-being, the primary objective of the study is to assess patients' quality of life. Further patient-relevant endpoints addressed by this study will include seizure burden, PFS, Objective Response Rate (ORR), TTNI, safety as well as factors affecting treatment decision making.
Adult patients (at least 40 kg) with predominantly non-enhancing grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
oral, first-in-class, dual inhibitor of mIDH 1 and 2
Evaluate Quality of Life (QoL) by the Functional Assessment of Cancer Therapy - Brain (FACT-Br) questionnaire over the course of treatment
Evaluate QoL by the FACT-Br questionnaire over the course of treatment. Change from baseline in the FACT-Br total score over time. The FACT-Br total score ranges from 0 to 200, with higher scores indicating better quality of life.
Time frame: baseline, up to 72 months
Evaluate Quality of Life (QoL) by using the Functional Assessment of Cancer Therapy - Brain (FACT-Br) questionnaire at start and during course of vorasidenib treatment
Evaluate QoL by using the FACT-Br questionnaire at start and during course of vorasidenib treatment. Change from baseline over time for all other scales of the FACT-Br. For all scales, the higher the score the better quality of life.
Time frame: baseline, up to 72 months
Assess seizure activity and severity at baseline and during treatment: Proportion of patients with baseline seizure activity
Proportion of patients with baseline seizure activity is defined as at least 1 seizure in the previous 30 days prior to vorasidenib treatment start
Time frame: baseline, up to 72 months
Assess seizure activity and severity at baseline and during treatment: event rate of seizures
Exposure adjusted event rate of seizures according to patient-reported outcome (patient diary)
Time frame: baseline, up to 72 months
Assess seizure activity and severity at baseline and during treatment: event rate of seizures with loss of consciousness
Exposure adjusted event rate of seizures with loss of consciousness according to PRO (patient diary)
Time frame: baseline, up to 72 months
Assess seizure activity and severity at baseline and during treatment: incidence rate of seizures
Exposure adjusted incidence rate of seizures according to patient-recorded outcome
Time frame: baseline, up to 72 months
Assess seizure activity and severity at baseline and during treatment: incidence rate of seizures with loss of consciousness
Exposure adjusted incidence rate of seizures according to patient-reported outcome
Time frame: baseline, up to 72 months
Assess seizure activity and severity at baseline and during treatment: Change from baseline of seizures
Change from baseline of seizures reported by the patients during course of treatment
Time frame: max. 72 months; from patient-specific study start to end of study (during vorasidenib treatment and follow-up)
Assess seizure activity and severity at baseline and during treatment: Change from baseline of seizures with loss of consciousness
Change from baseline of seizures with loss of consciousness reported by the patients during course of treatment
Time frame: baseline, up to 72 months
Assess effectiveness in routine treatment: Progression-free survival
PFS ist defined as time interval measured from the day of first vorasidenib administration to first progression or death, whichever comes first. Patients without tumor progression or death at the time of analysis will be censored at their date of last contact.
Time frame: baseline, up to 72 months
Assess effectiveness in routine treatment: Overall Survival (OS)
OS is defined as the time interval measured form the day of first vorasidenib administration to time of death from any cause. Time to last contact will be used if a patient has no documented date of death and OS for the patient will be considered censored.
Time frame: baseline, up to 72 months
Assess effectiveness in routine treatment: Objective response rate (ORR)
ORR is defined as the proportion of patients achieving Complete Response (CR), Partial Response (PR), or Minor Response (MR) as best response.
Time frame: max. 72 months; from patient-specific study start to end of study (during vorasidenib treatment and follow-up)
Assess effectiveness in routine treatment: Disease Control Rate (DCR)
DCR is defined as proportion of patients with Complete Response, Partial Response, Minor Response or Stable Disease as best response.
Time frame: baseline, up to 72 months
Assess effectiveness in routine treatment: Best response
Best response is defined as Complete Response (CR), Partial Response (PR), Minor Response (MR), Stable Disease (SD), or Progressive Disease (PD))
Time frame: baseline, up to 72 months
Assess effectiveness in routine treatment: Time to next intervention (TTNI)
Time to next intervention is defined as time from first administration of vorasidenib until initiation of next intervention (i.e., subsequent antineoplastic treatment, surgery, chemotherapy or radiotherapy) or death, whichever comes first.
Time frame: baseline, up to 72 months
Assess drug safety: Incidence of (serious) adverse events ((S)AEs)
Incidence of (serious) AEs ((S)AEs) as characterized by type, frequency, severity and seriousness.
Time frame: Baseline up to 30 days after vorasidenib treatment
Assess drug safety: Incidence of (serious) adverse drug reactions ((S)ADRs)
Incidence of (serious) adverse drug reactions ((S)ADRs) as characterized by type, frequency, severity and seriousness.
Time frame: Baseline up to 30 days after vorasidenib treatment
Assess drug safety: Incidence of seizures reported as treatment-emergent adverse events (TEAEs)
Treatment-emergent adverse events (TEAE) are adverse events that were not present before medical treatment, or a pre-existing event that worsens in intensity or frequency during vorasidenib treatment and the following 30 days.
Time frame: Baseline up to 30 days after vorasidenib treatment
Assess parameters of physicians' treatment decision making using a questionnaire
Frequency of distinct parameters affecting therapy choice; questionnaire completed by treating physician.
Time frame: Baseline
Duration of treatment with vorasidenib
Describe treatment reality in detail: Duration of treatment with vorasidenib
Time frame: baseline, up to 72 months
Frequency of treatment modifications with reasons
Describe treatment reality in detail: Frequency of treatment modifications with reasons
Time frame: baseline, up to 72 months
Time to start of vorasidenib treatment after initial diagnosis
Describe treatment reality in detail: Time to start of vorasidenib treatment after initial diagnosis
Time frame: Baseline
Time to start of vorasidenib treatment after surgery
Describe treatment reality in detail: Time to start of vorasidenib treatment after surgery
Time frame: Baseline
Frequency of distinct subsequent antineoplastic therapies (systemic therapies including substances, surgeries, radiotherapies)
Describe treatment reality in detail: Frequency of distinct subsequent antineoplastic therapies (systemic therapies including substances, surgeries, radiotherapies)
Time frame: baseline, up to 72 months
Anti-epileptic medication: Proportion of patients with anti-epileptic drug (AED) treatment at baseline
Proportion of patients with anti-epileptic drug treatment at baseline (i.e. 30 days prior treatment)
Time frame: baseline, up to 72 months
Anti-epileptic medication: Proportion of patients with AED treatment during treatment
Proportion of patients with anti-epileptic drug treatment during treatment
Time frame: baseline, up to 72 months
Anti-epileptic medication: Type of AED
Anti-epileptic medication during course of treatment
Time frame: baseline, up to 72 months
Anti-epileptic medication: Doses of AED
Doses of anti-epileptic medication over the course of time
Time frame: baseline, up to 72 months
Anti-epileptic medication: AED modifications
Type of anti-epileptic medication modifications
Time frame: baseline, up to 72 months
Anti-epileptic medication: Reasons for AED modifications
Anti-epileptic medication modifications with reasons thereof
Time frame: baseline, up to 72 months
Anti-epileptic medication: Frequency of patients under AED treatment after End of Treatment (EOT) of vorasidenib
Frequency of patients under AED treatment after EOT of vorasidenib (incl. dose)
Time frame: from end of treatment to end of study, up to 72 months
Started Dec 2025 (actual). Primary completion is estimated for Nov 2031, 71 months after the start.
Of 125 observational studies under Glioma, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 104. This study's planned 71 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.